Top generic drug companies in fray for Novartis' brands
Saturday, April 1, 2017, 8:59 PM
Leading Indian generic drug makers Lupin, Cipla, Zydus Cadila and Sun are eyeing to acquire the respiratory drugs portfolio of Novartis AG that the Swiss giant is seeking to divest. The portfolio of brands on offer could fetch as much as $500 million in a sale. The Novartis portfolio includes top-selling brand TOBI Podhaler, a drug prescribed for symptomatic relief-to-patients suffering from cystic fibrosis.